Team Kendall's Social Media

  • Wix Facebook page
  • Instagram Social Icon

Friedreich's Ataxia Treatment Advancement

January 21, 2014

The Friedreich's Ataxia Research Alliance announced today that BioMarin Pharmaceutical, a company with a strong commitment and success in developing treatments for rare diseases, will be taking the Histone DeACetylase (HDAC) inhibitor program forward. Click here to access FARA's press release as well as a press release from Repligen and BioMarin


With this exciting news, we are reminded of the important work our donations fund. Thank you to everyone who has had a part in making this happen. We are moving forward to finding a cure for Friedreich's Ataxia! 

Please reload

Featured Posts

What Fundraising Means to Me

March 7, 2019

Please reload

recent posts

January 5, 2020

December 18, 2019

December 12, 2019

December 6, 2019

November 26, 2019

November 22, 2019

November 18, 2019

October 17, 2019

Please reload